This study investigates differences in μ-opioid receptor mediated neurotransmission in healthy controls and overnight-abstinent smokers, and potential effects of the OPRM1 A118G genotype. It also examines the effects of smoking denicotinized (DN) and average nicotine (N) cigarettes on the μ-opioid system. Positron emission tomography with 11 C-carfentanil was used to determine regional brain μ-opioid receptor (MOR) availability (non-displaceable binding potential, BP ND ) in a sample of 19 male smokers and 22 nonsmoking control subjects. Nonsmokers showed greater MOR BP ND than overnight abstinent smokers in the basal ganglia and thalamus. BP ND in the basal ganglia was negatively correlated with baseline craving levels and Fagerström scores. Interactions between group and genotype were seen in the nucleus accumbens bilaterally and the amygdala, with Gallele carriers demonstrating lower BP ND in these regions, but only among smokers. After smoking the DN cigarette, smokers showed evidence of MOR activation in the thalamus and nucleus accumbens. No additional activation was observed after the N cigarette, with a mean effect of increases in MOR BP ND (i.e., deactivation) with respect to the DN cigarette effects in the thalamus and left amygdala. Changes in MOR BP ND were related to both Fagerström scores and changes in craving. This study showed that overnight-abstinent smokers have lower concentrations of available MORs than controls, an effect that was related to both craving and the severity of addiction. It also suggests that nicotine non-specific elements of the smoking experience have an important role in regulating MOR-mediated neurotransmission, and in turn modulating withdrawal-induced craving ratings.
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With over one billion smokers worldwide, nicotine dependence is a major health concern. There are more than 5 million deaths associated with tobacco each year, and tobacco smoking is the most prevalent cause of "preventable disease and death" in the United States (Graul and Prous, 2005) . There are substantial lines of evidence pointing to a strong link between nicotine use and endogenous μ-opioid mechanisms, which may mediate some of nicotine's addictive properties and distress during withdrawal (for review see Pomerleau, 1998).
Animal and cell culture studies suggest that acute nicotine induces endogenous opioid release (Boyadjieva and Sarkar, 1997; Davenport et al., 1990) . However, attempts to translate these initial findings into human studies have led to inconsistent results. Studies examining changes in MOR availability (binding potential, BP) after smoking denicotinized (DN) versus average nicotine (N) cigarettes with positron emission tomography (PET), an indirect measure of changes in neurotransmitter release and μ-opioid receptor activation, have found both reductions in BP (suggesting activation of neurotransmission) and increases (deactivation) in different regions of the brain (Domino et al., 2015; Scott et al., 2006) . Alternatively, some studies have not found any significant differences in MOR binding after smoking N versus DN cigarettes (Kuwabara et al., 2014; Ray et al., 2011) . Measures at baseline have also shown either lower MOR BP in smokers compared to nonsmoking controls (Scott et al., 2006) , or no significant differences between groups (Kuwabara et al., 2014) . The μ-opioid system is known to respond to positive expectancies, including the so-called placebo effect (Pecina et al., 2015a; Scott et al., 2008; Zubieta et al., 2005) , which may impact the effects of both DN and N smoking. This effect
